Gilead Sciences completes acquisition of CV Therapeutics

FOSTER CITY, Calif. Gilead Sciences has completed its $1.4 billion takeover of CV Therapeutics, the drug maker announced Wednesday.

The company said it tendered more than 88% of outstanding shares of common stock of CV by the close of business Tuesday.

Gilead announced the takeover of CV last month amid a wave of acquisitions among large pharmaceutical companies.